

22 April 2022

DIAGNOSIS AND TREATMENT OF IMMUNE THROMBOCYTOPENIA

Q1. In the last 6 months, how many patients has your trust treated (for any condition) with the following treatments

- **Avatrombopag** <5 patients
- **Eltrombopag** 28 patients
- **Fostamatinib** <5 patients
- **Romiplostim** 11 patients

**<5 has been stated rather than the actual figure in order to ensure our patients remain non-identifiable*

Q2. In the last 6 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3)?

Belfast Trust Patient Inpatients & Daycases Coded with a Primary Diagnosis of D69.3 Immune Thrombocytopenia: August 2021 - January 2022

Primary Diagnosis	Total
D69.3	119

Q3. In the last 6 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:

- **Avatrombopag**
- **Mycophenolate mofetil**
- **Rituximab**
- **Surgery (splenectomy)**

Unable to break down as above. Instead, see below:-

Belfast Trust Patients Coded with a Primary Diagnosis of D69.3 Immune Thrombocytopenia with a Splenectomy Procedure: August 2021 - January 2022

Primary Diagnosis D69.3 with Splenectomy Procedure	Total
	0

22 April 2022

Q4. Does your trust participate in any clinical trials for the treatment of Immune thrombocytopenia? If so, can you please provide the name of each trial and the number of patients taking part.

We don't participate in any clinical trials at present